Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease.
Yoo T, Joo SK, Kim HJ, Kim HY, Sim H, Lee J, Kim HH, Jung S, Lee Y, Jamialahmadi O, Romeo S, Jeong WI, Hwang GS, Kang KW, Kim JW, Kim W, Choi M; Innovative Target Exploration of NAFLD (ITEN) consortium.
Yoo T, et al. Among authors: jung s.
J Hepatol. 2021 Sep;75(3):514-523. doi: 10.1016/j.jhep.2021.04.011. Epub 2021 Apr 20.
J Hepatol. 2021.
PMID: 33892010